TUNING PRODUCTS FOR FREE AIRWAVES
Article Abstract:
The Government of India has reviewed the price of the de- controlled products under the Drug Price Control Order (DPCO). It has brought IV (intra-venous) fluids under the purview of price control. The National Pharmaceutical Pricing Authority (NPPA) was set up in September 1997 to administer DPCO as the official body. NPPA is also entrusted with price regulations, fixing fines for violations of price regulation and their collection. Recently, NPPA revised the prices of Ranitidine which was opposed by Glaxo, Cheminor Drugs and Ranbaxy on the grounds that its calculations were based on outdated data. The multinational companies are most hit by the DPCO as their products up to 50-75 percent are under price control. Novartis has 20 percent, Hoechst Marion Roussel 60 percent and Glaxo 60 percent of their products under price control. Indian pharmaceutical companies have 15-30 percent of their products under price control. Pfizer has reduced its products under price control. The companies have changed the composition of the formulations, transferring the brand to small-scale units and discontinued making the products completely. Arthur D Little has pointed out that the prices of cardio-vascular drugs in India, like Atenolol and Enalapril, are 25-30 percent lesser than those in USA. The 2 drugs are cheaper by 12-16 percent than in UK. The OPPI has suggested to the Government of India that price controls should be removed gradually. It has suggested de-control of 17 bulk drugs. The remaining 57 drugs should be de-controlled - 19 drugs every 6 months. DPCO has sought increasing the mark-up price from 100 percent to 150 percent and that of the packing costs by 20 percent. All price increases should be implemented within 30 days after submission of relevant data. (rk)
Comment:
India: Government has reviewed the price of the de-controlled products under the Drug Price Control Order
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
SHREE RAMA DEBENTURE ISSUE
Article Abstract:
The 2 debenture issues of Rs25 crore each of Shree Rama Multi- Tech Ltd have been rated as A by the Credit Analysis & Research Ltd (CARE), indicating adequate safety as its gearing was 0.51 as on September 30, 1998. (rk) (kvr)
Comment:
The 2 debenture issues of Rs25 crore each of Shree Rama Multi- Tech Ltd have been rated as A by the Credit Analysis & Research Ltd (CARE), indicating adequate safety as its gearing was 0.51 as on September 30, 1998.
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: US PUTS CURBS ON 63 RESEARCH LABS OF SHRIMPS AND TURTLES. CALL RATES ZOOM TO 24 PC, END AT 21 PC
- Abstracts: BANK(ING) EXTRAORDINARY KREST FIN ORDERED TO REPAY DEPOSITS
- Abstracts: PATEL ENGG ACQUIRES US FIRM FOR $2.68 M THREE SUITORS LINE UP FOR VIP'S FURNITURE BUSINESS. OMAN OIL MAY PICK UP STAKE IN ESSAR OIL
- Abstracts: RUM BRAND IN COURT FOR HURTING THE SPIRIT. McDOWELL LAUNCHES NEW WHISKY BRAND
- Abstracts: UPASI - EMERGING TRENDS IN CONSUMER MARKETING WGC SEES 8% RISE IN INDIA'S GOLD DEMAND THIS YEAR